Literature DB >> 1706636

MPTP-treated young mice but not aging mice show partial recovery of the nigrostriatal dopaminergic system by stereotaxic injection of acidic fibroblast growth factor (aFGF).

I Date1, M F Notter, S Y Felten, D L Felten.   

Abstract

Acidic fibroblast growth factor (aFGF) is a heparin-binding polypeptide that acts as a neurotrophic factor for certain central and peripheral neurons. Acidic FGF was injected stereotaxically into the striatum of young (2-month-old) and aging (12-month-old) C57BL/6 mice that were treated 1 week before with systemic injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). MPTP treatment (4 x 20 mg/kg, i.p. given 12 h apart) reduced tyrosine hydroxylase (TH)-immunoreactive (IR) fibers in the striatum and reduced dopamine (DA) concentration to 32% of the controls in young and 20% of the controls in aging mouse brain 5 weeks after administration. Although the DA concentration recovered to 43% of the controls in young mice following stereotaxic injection of aFGF 5 weeks after MPTP treatment, aging mice with such treatment did not show a significant recovery of DA concentration. Computerized image analysis of TH-IR fibers in the striatum also showed significant recovery in young mice treated with aFGF, while aging mice did not show a significant recovery. We conclude that treatment of MPTP-depleted young mice with aFGF results in partial recovery in the nigrostriatal DA system but such benefits decline with age.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1706636     DOI: 10.1016/0006-8993(90)90264-c

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  19 in total

Review 1.  Neural transplantation for Parkinson's disease.

Authors:  I Date; T Ohmoto
Journal:  Cell Mol Neurobiol       Date:  1999-02       Impact factor: 5.046

2.  GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis.

Authors:  C M Kearns; W A Cass; K Smoot; R Kryscio; D M Gash
Journal:  J Neurosci       Date:  1997-09-15       Impact factor: 6.167

3.  Neurotrophic factors in neurodegenerative disorders: model of Parkinson's disease.

Authors:  J Garcia de Yebenes; J Yebenes; M A Mena
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

4.  Expression of acidic and basic fibroblast growth factors in the substantia nigra of rat, monkey, and human.

Authors:  A J Bean; R Elde; Y H Cao; C Oellig; C Tamminga; M Goldstein; R F Pettersson; T Hökfelt
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

5.  Fibroblast growth factor 1attenuates 6-hydroxydopamine-induced neurotoxicity: an in vitro and in vivo investigation in experimental models of parkinson's disease.

Authors:  Xiaojie Wei; Songbin He; Zhouguang Wang; Jiamin Wu; Jinjing Zhang; Yi Cheng; Jie Yang; Xinlong Xu; Zaifeng Chen; Junmin Ye; Li Chen; Li Lin; Jian Xiao
Journal:  Am J Transl Res       Date:  2014-11-22       Impact factor: 4.060

Review 6.  A scientific rationale for protective therapy in Parkinson's disease.

Authors:  C W Olanow
Journal:  J Neural Transm Gen Sect       Date:  1993

Review 7.  Biochemistry of Parkinson's disease with special reference to the dopaminergic systems.

Authors:  E C Hirsch
Journal:  Mol Neurobiol       Date:  1994 Aug-Dec       Impact factor: 5.590

Review 8.  Neurotrophic factors for the investigation and treatment of movement disorders.

Authors:  Justo Garcia De Yébenes; Marina Sánchez; Maria Angeles Mena
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

9.  Administration of FGF-1 through transfected cells alleviates MPTP toxicity in mice.

Authors:  R N McLay; S M Freeman; J E Zadina
Journal:  Neurotox Res       Date:  2001-07       Impact factor: 3.911

10.  Platelet-derived growth factor promotes survival of rat and human mesencephalic dopaminergic neurons in culture.

Authors:  G Nikkhah; P Odin; A Smits; A Tingström; A Othberg; P Brundin; K Funa; O Lindvall
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.